ArticleDrug and alcohol review2026
Calcitonin Gene-Related Peptide Signalling in Alcohol Use Disorders: A Scoping Review.
Article in Drug and alcohol review, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
issueAlcohol use disorders (AUD) represent a major global health burden, and currently available pharmacological treatments show limited and heterogeneous efficacy. Calcitonin gene-related peptide (CGRP) is a pleiotropic neuropeptide involved in stress regulation and neuroimmune signalling, and is an established therapeutic target in migraine. CGRP signalling may also be involved in alcohol-related mechanisms, raising interest in its potential relevance for AUDs. APPROACH: We conducted a scoping review of original studies investigating CGRP and CGRP-related pathways in the context of alcohol exposure and AUDs. A systematic literature search was performed in PubMed, Embase, Cochrane Library, PsycINFO and Scopus. Animal and human studies published in English were included and synthesised narratively. KEY
findingsThirty studies met the inclusion criteria, including 26 animal studies and 4 human studies. IMPLICATIONS: Preclinical evidence indicates that CGRP plays a context-dependent role in AUD-related mechanisms, modulating stress-related drinking, withdrawal-associated adaptations and alcohol-induced nociceptive sensitisation rather than directly driving alcohol consumption. In peripheral tissues, CGRP exerts protective effects against ethanol-induced gastric and pulmonary injury. Human studies were limited and largely observational and showed altered CGRP biology in advanced alcohol-related liver disease, suggesting a compensatory or homeostatic role.
conclusionsCGRP represents a biologically relevant but complex target in AUDs, with both potential therapeutic and protective roles depending on the clinical context. Anti-CGRP therapies may warrant exploration in carefully selected scenarios, such as alcohol-related headache or stress-associated symptoms during withdrawal in non-cirrhotic patients. Given the homeostatic functions of CGRP, any pharmacological modulation should be cautiously evaluated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.